

SARS-CoV-2 antigen immunoassay manuscript submitted 9 April

1 **Multicenter evaluation of a fully automated high-throughput SARS-CoV-2**
2 **antigen immunoassay**

3

4 Dominik Nörz^{1*}, Flaminia Olearo^{1*}, Stojan Perisic², Matthias Bauer³, Elena Riester⁴, Tanja Schneider⁵,
5 Kathrin Schönfeld⁵, Tina Laengin⁵, and Marc Lütgehetmann¹

6

7 ¹Center for Diagnostics, Institute of Medical Microbiology, Virology and Hygiene, University Medical
8 Center Hamburg-Eppendorf (UKE), Hamburg, Germany

9 ²Hospital of Stuttgart, Institute for Clinical Chemistry and Laboratory Medicine, Stuttgart, Germany

10 ³Hospital of Ludwigshafen, Institute for Laboratory Medicine, Ludwigshafen, Germany

11 ⁴Labor Augsburg MVZ GmbH, Augsburg, Germany

12 ⁵Roche Diagnostics GmbH, Penzberg, Germany

13

14 *Contributed equally to this work

15

16 **Keywords:**

17 SARS-CoV-2

18 Antigen immunoassay

19 High-throughput platform

20

21 **Corresponding author:**

22 Marc Lütgehetmann

23 Institute of Medical Microbiology, Virology and Hygiene

24 Martinstraße 52

25 D-20246 Hamburg

26 mluetgeh@uke.de

27 Target journals: **medRxiv** and **Journal of Clinical Microbiology**

28 **1 Abstract**

29 **Background:** Molecular testing for SARS-CoV-2 continues to suffer from delays and
30 shortages. Antigen tests have recently emerged as a viable alternative to detect patients
31 with high viral loads, associated with elevated risk of transmission. While rapid lateral flow
32 tests greatly improved accessibility of SARS-CoV-2 detection in critical areas, their manual
33 nature limits scalability and suitability for large-scale testing schemes. The Elecsys® SARS-
34 CoV-2 Antigen assay allows antigen immunoassays to be carried out on fully automated
35 high-throughput serology platforms. **Methods:** A total of 3139 nasopharyngeal and
36 oropharyngeal swabs were collected at 3 different testing sites in Germany. Swab samples
37 were pre-characterized by RT-qPCR and consecutively subjected to the antigen
38 immunoassay on either the cobas e411 or cobas e801 analyzers. **Results:** Of the tested
39 respiratory samples, 392 were PCR positive for SARS-CoV-2 RNA. Median concentration was
40 2.95×10^4 (interquartile range [IQR] 5.1×10^2 – 3.5×10^6) copies/mL. Overall sensitivity and
41 specificity of the antigen immunoassay were 60.5% (95% confidence interval [CI] 55.5–65.4)
42 and 99.9% (95% CI 99.6–100), respectively. A 93.7% (95% CI 89.7–96.5) sensitivity was
43 achieved at a viral RNA concentration $\geq 10^4$ copies/mL (~cycle threshold (Ct) value < 29.9).
44 **Conclusion:** The Elecsys SARS-CoV-2 Antigen assay reliably detected patient samples with
45 viral loads of 10,000 copies/mL and higher. It thus represents a viable high-throughput
46 alternative for pre-screening of patients, or in situations where PCR testing is not readily
47 available.

48

49 **2 Introduction**

50 RT-qPCR remains the gold standard for detection of SARS-CoV-2 in clinical specimens due to
51 its unparalleled analytic accuracy (1, 2). However, the sudden surge in demand for molecular
52 testing continues to overstretch the capacity of both diagnostic laboratories and reagent
53 suppliers, leading to reporting delays and sometimes inadequate availability of testing where
54 it is urgently needed. SARS-CoV-2 antigen immunoassays have recently emerged as an
55 alternative to nucleic acid amplification tests, most prolifically in the form of rapid, point-of-
56 care, lateral flow tests (LFTs) (3-5). Despite their inherent disadvantage in sensitivity
57 compared with PCR, mathematical modeling suggests that tests could be effective for
58 infection control if appropriate testing frequency were adopted (6). Using currently available
59 rapid antigen tests for mass testing does however bring about additional challenges, as this
60 assay format is highly manual in nature and largely unsuitable for automation. Moving the
61 SARS-CoV-2 antigen assay from LFT to a high-throughput immunoanalyzer using
62 electrochemiluminescence detection technology could improve those issues, while further
63 increasing overall testing capacity. The aim of this study was to evaluate the sensitivity and
64 specificity of the new fully automated Elecsys® SARS-CoV-2 Antigen assay, using samples
65 characterized by the gold standard: RT-qPCR.

66 **3 Materials and methods**

67 **3.1 Samples**

68 In this multicenter study, nasopharyngeal and oropharyngeal samples were tested following
69 routine diagnostics at the University Medical Center Hamburg-Eppendorf, the Hospital of
70 Stuttgart, and Hospital Ludwigshafen (see **Supplementary Table 1**). Overall, the study
71 comprised a total of 3139 nasopharyngeal and oropharyngeal swab samples, including 1331
72 samples from the Hospital of Stuttgart, 1058 samples from University Medical Center
73 Hamburg-Eppendorf, and 647 samples from Hospital Ludwigshafen, as well as 103 banked
74 nasopharyngeal samples in universal viral transport (UVT) system from a commercial vendor
75 (Boca Biolistics, Pompano Beach, FL, USA). Specimens were collected in November 2020, in 3
76 mL of Copan Universal Transport Medium (UTM-RT, Copan, Brescia, Italy) or BD Universal
77 Viral Transport (UVT, Becton, Dickinson, Sparks, MD, USA) using flocked swabs.

78 This study was conducted in accordance with applicable regulations, the study protocol
79 provided by Roche Diagnostics, and the principles of the Declaration of Helsinki. The use of
80 anonymized remnant samples material was approved by ethical review committees prior to
81 study initiation (ethics committee names and approval numbers: Ethik-Kommission bei der
82 Landesärztekammer Baden-Württemberg; F-2020-154 [Stuttgart]; Ethik-Kommission der
83 Ärztekammer Hamburg; WF-184/20 [Hamburg]; Ethik-Kommission bei der
84 Landesärztekammer Rheinland-Pfalz: 2020-15449[Ludwigshafen]).

85 **3.2 Antigen assay and RT-qPCR**

86 Antigen detection was performed at two testing sites (Hamburg and Augsburg) using the
87 Elecys SARS-CoV-2 Antigen assay on the cobas® e 411 and cobas e 801 immunoanalyzers.
88 The Elecys SARS-CoV-2 Antigen assay (Roche Diagnostics International Ltd, Rotkreuz,
89 Switzerland) is an automated electrochemiluminescence immunoassay (ECLIA), developed
90 for *in vitro* qualitative detection of SARS-CoV-2 antigen. It utilizes monoclonal antibodies
91 directed against the SARS-CoV-2 nucleocapsid protein in an antibody sandwich assay format
92 for the detection of SARS-CoV-2 in upper respiratory tract specimens (7). The time to result
93 for the assay can be as little as 18 minutes, and the analyzer automatically calculates a cut-
94 off based on the measurement of two calibrators: one negative (COV2AG Cal1) and one
95 positive (COV2AG Cal2). The results obtained are interpreted as recommended by the
96 manufacturer as either 'reactive' or 'non-reactive' in the form of a cut-off index (COI), i.e.
97 'non-reactive' if COI <1.0 or 'reactive' if COI ≥1.0.

98 RT-qPCR testing was performed with the qualitative cobas® SARS-CoV-2 assay on the cobas
99 6800 system (Roche Molecular Systems, Inc., Branchburg, NJ, USA), according to
100 manufacturer's instructions (8). Target-1 (ORF1ab) and Target-2 (E-gene) were analyzed
101 separately. All samples with a valid result for Target-2 and/or Target-1 were included in the
102 analysis for comparison with the SARS-CoV-2 Antigen assay (from a total of 3139 samples).
103 Quantification was performed using cycle threshold (Ct) values of Target-2 (9) using
104 reference material by Qnostics Ltd. (Glasgow, UK) as the quantification standard. The
105 formula for conversion Ct value (Target-2) to log₁₀ copies/mL is (Ct × -0.30769) +13.2. The
106 lower limit of quantification was set to Ct=33 corresponding to 1000 copies SARS-CoV-2

107 RNA/mL, in accordance with previous studies (9). Two samples included in this study were
108 negative for Target-2, but positive for Target-1 at late Ct (>35), well beyond linear range.
109 These samples were integrated into the sample set with a presumed viral RNA concentration
110 of $<10^3$ copies/mL.

111 **3.3 Statistics**

112 Sensitivity and specificity, including 95% confidence intervals (CIs), were assessed as per
113 Altman (10). Pearson correlation was used for linear regression. The significance threshold
114 was set at a two-sided alpha value of 0.05. Statistical analysis was performed with STATA
115 (version 15) and GraphPad Prism (version 86 9.0.0).

116 **4 Results**

117 A total of 3139 respiratory samples were analyzed in this study (see also **Supplementary**
118 **Table 1**). Three hundred and ninety-two samples were SARS-CoV-2 RNA positive and 2747
119 samples were SARS-CoV-2 RNA negative. For PCR-positive samples, 79/392 (20.2%) patients
120 were asymptomatic and 79.8% (313/392) were symptomatic, with 47.6% (149/313) of
121 samples collected within the first 5 days of symptom onset. The median concentration of
122 viral RNA was 2.95×10^4 SARS-CoV-2 copies/mL (interquartile range [IQR] 5.1×10^2 – 3.5×10^6
123 SARS-CoV-2 RNA copies/mL; **Figure 1A**). In total, 236/392 samples were detected as reactive
124 for SARS-CoV-2 antigen with the Elecsys assay, with a median COI value of 46.0 (IQR 6.0–
125 701.3). Distribution of the results for the PCR-positive and PCR-negative groups is shown in
126 **Figure 1B**. The overall sensitivity and specificity were 60.2% (95% CI 55.2–65.1, number of

127 samples [N]=392) and 99.9% (95% CI 99.6–100, N=2747), respectively (**Table 1**). The
128 cumulative sensitivity was 93.7%, 100%, and 100% for samples with >10,000 copies (~Ct
129 <29.9), 100,000 copies (~Ct <26.6), and 1,000,000 copies (~Ct <23.0) (**Table 1**), respectively.
130 For samples from symptomatic patients, the assay reached an overall relative sensitivity of
131 68.4% (95% CI 62.9–73.5, N=313), increasing to 83.2% (95% CI 76.2–88.8, N=149) if
132 symptoms had manifested within the last 5 days (**Supplementary Table 2**). On the other
133 hand, the overall sensitivity observed in asymptomatic patients was only 27.8% (95% CI
134 18.3–39.1, N=79). Relative sensitivities corresponded with high RNA levels and gradually
135 decreased as RNA levels decreased. A considerable increase in sensitivity was observed
136 when analysis was limited to samples containing >10,000 copies/mL, reaching 95.9% (95% CI
137 92.2–98.2, N=197) for symptomatic patients and 76.9% (95% CI 56.4–91.0, N=26) for
138 asymptomatic patients (**Supplementary Table 2**).

139 To analyze the overall assay performance, samples were sorted by SARS-CoV-2 RNA
140 copies/mL and individual sensitivities calculated for sets of 20 samples (shown using a heat
141 map in **Figure 2A**). Of note, the sensitivity of the assay was 95% and 50% at concentrations
142 of around 2×10^5 and 2×10^4 – 5×10^3 viral copies/mL, respectively, but <10% for samples with
143 $<10^3$ copies/mL. When the analysis was focused on samples containing RNA levels beyond
144 95% sensitivity of the immunoassay (10,000 copies/mL; Ct <29.9), a significant linear
145 correlation was observed between the Elecsys SARS-CoV-2 Antigen COI value and SARS-CoV-
146 2 RNA copies/mL ($p < 0.0001$; $r^2 = 0.786$; **Figure 2B**). Also, in this group, a sensitivity of 98.3%
147 (95% CI 94.0–99.8) was achieved in the sub-analysis of patients tested less than 5 days after
148 symptom onset.

149

150 **5 Discussion**

151 The introduction of rapid SARS-CoV-2 antigen testing into the market was met with a lot of
152 initial enthusiasm due to the promise of broad availability and easy application. While there
153 are many different methods for antigen detection in clinical practice, such as enzyme-linked
154 immunosorbent assays and ECLIA, the first wave of commercial tests consisted
155 predominantly of rapid, point-of-care LFTs with optical read-outs. Preliminary performance
156 data demonstrated good sensitivity in high-viral-load samples, but low concentrations of
157 virus are frequently missed, thus leading to the sobering conclusion that antigen tests
158 cannot provide the same definitive results as RT-qPCR (5, 11-13). Although PCR tests are
159 analytically superior by a considerable margin, their effectiveness for infection control has
160 often been hampered by supply shortages and reporting delays.

161 Recent studies have shown a correlation between the probability of recovering infectious
162 virus from clinical samples and the time of onset of symptoms, as well as RNA
163 concentrations ($>1 \times 10^6$ copies/mL) within the specimen (14, 15). This suggests that the risk
164 of transmission is highest during the early stages of disease, when viral titers are at their
165 peak, which would also facilitate detection by antigen test. It has further been suggested
166 that a low sensitivity test can be just as effective at detecting infections as a highly sensitive
167 one, if testing can be made possible at increased frequency (6). Most currently available
168 SARS-CoV-2 antigen tests utilize a rapid, point-of-care LFT format, thus relying on a high
169 degree of human interaction. They are largely unsuitable for automation and additional
170 human operators are required at the same proportion as testing capacity is scaled up. While

171 there are clear benefits of a point-of-care test that can be carried out with minimal training
172 and requiring no specialized equipment (16), testing en masse (e.g. in healthcare facilities) is
173 vastly more efficient when performed automatically using high-throughput immunoassay
174 platforms.

175 In this study, we stratified samples to assess the relative sensitivity of the new Elecsys SARS-
176 CoV-2 Antigen assay for the cobas immunoassay analyzer systems using the gold standard,
177 RT-qPCR. Although the overall relative sensitivity for the entire sample set was 60.2%,
178 among those patients that were tested in the first 5 days from the onset of symptoms, the
179 sensitivity increased to 83.2%. Furthermore, the Elecsys SARS-CoV-2 Antigen assay was able
180 to detect 93.7% of patients with elevated risk of transmission (Ct <30 and accordingly
181 c(RNA) > 10,000 copies/mL). Overall relative specificity was determined as 99.9% in a total of
182 2747 negative samples. These results are in line with existing preliminary data on the clinical
183 performance of other available SARS-CoV-2 antigen tests (12, 17), including other high-
184 throughput SARS-CoV-2 antigen tests like the Lumipulse (18), demonstrating a cumulative
185 sensitivity of 55.2% compared with PCR. While head-to-head studies are needed to compare
186 the different systems on the market, the high-throughput SARS-CoV-2 antigen assays might
187 be a valuable analytic option in the coming months in the struggle to control the pandemic.

188

189 **6 Conclusion**

190 The novel Elecsys SARS-CoV-2 Antigen immunoassay showed good performance in a broad
191 set of clinical samples compared to RT-PCR. It demonstrated a high reliability in detecting

192 samples containing high concentrations of viral RNA, indicative of high transmission
193 potential. Furthermore, a relative specificity of 99.9% ensures a minimal rate of false-
194 positives, consequently saving resources on confirmation-testing and unnecessary
195 quarantine. The ability to run the test on high-throughput immunoassay platforms, and a
196 time-to-result of approximately 18 minutes, allow for en masse deployment of SARS-CoV-2
197 antigen testing, for example in the context of centralized large-scale testing schemes.

198 **7 Author contribution**

199 TL, TS, and KS developed the study conceptualization and design and study protocol, and
200 managed the study conduct, database generation and data validation. ML, SP, and MB
201 provided sample material and ML, SP, and ER generated data during study testing. ML, TS,
202 and TL conceived the original idea of the manuscript. DN, FO, ML, and TS formally analyzed
203 the data and its representations for the manuscript. DN, ML, and FO drafted the manuscript
204 and interpreted the data with critical input from TS and TL. All authors reviewed and revised
205 the manuscript and approved it for publication.

206 **8 Conflict of interest**

207 Tanja Schneider, Kathrin Schönfeld, and Tina Laengin are employees of Roche Diagnostics
208 GmbH. Marc Lütgehetmann has received speaker's honoraria and related travel expenses
209 from Roche Diagnostics. Elena Riester has received speaker's honorarium from Roche. Stojan
210 Perisic, Flaminia Olearo, Matthias F. Bauer and Dominik Nörz have no conflicts to report. This
211 study was funded by Roche Diagnostics GmbH (Mannheim, Germany). Medical writing
212 support, under the direction of the authors, was provided by Tina Patrick (Elements

213 Communications Ltd, Westerham, Kent, UK) and was funded by Roche Diagnostics

214 International Ltd, Rotkreuz, Switzerland.

215 **9 Acknowledgements**

216 The authors thank: Serology team of the University Medical Center Hamburg-Eppendorf,

217 Institute of Medical Microbiology, Virology and Hygiene; the laboratory team of the Institute

218 of Laboratory Diagnostics, Hygiene and Transfusion Medicine at the Klinikum Ludwigshafen;

219 the Corona specimen acquisition team and its Coordinator Mr. OA Christian Menzel (Clinic of

220 Stuttgart), Corona testing facility team (Clinic of Stuttgart) as well as Ms. Pauline Weissleder

221 and Ms. Sina Semenowitsch (Clinic of Stuttgart) for great help with specimen handling and

222 data processing; Sigrid Reichhuber, Janina Edion, and Yvonne Knack (Roche Diagnostics) for

223 management of investigation sites, data acquisition, and study monitoring.

224 COBAS, COBAS E and ELECSYS are trademarks of Roche.

225 10 References

- 226 1. WHO. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases
227 2020. Available from: [https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117)
228 [coronavirus-in-suspected-human-cases-20200117](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117). Accessed February 15 2021.
- 229 2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019
230 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill.* 2020;25(3).
- 231 3. CDC. Interim Guidance for Antigen Testing for SARS-CoV-2 2020. Available from:
232 <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html>. Accessed
233 February 15 2021.
- 234 4. Igliński Z, Velzing J, van Beek J, van de Vijver D, Aron G, Ensing R, et al. Clinical evaluation of the
235 Roche/SD Biosensor rapid antigen test with symptomatic, non-hospitalized patients in a municipal
236 health service drive-through testing site. *medRxiv.* 2020:2020.11.18.20234104.
- 237 5. Olearo F, Nörz D, Heinrich F, Sutter JP, Rödel K, Schultze A, et al. Handling and accuracy of
238 four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR. *medRxiv.*
239 2020:2020.12.05.20244673.
- 240 6. Mina MJ, Parker R, Larremore DB. Rethinking covid-19 test sensitivity — a strategy for
241 containment. *New England Journal of Medicine.* 2020;383(22):e120.
- 242 7. Roche Diagnostics GmbH. Elecsys® Anti-SARS-CoV-2 method sheet v1. 2020. Available from:
243 <https://diagnostics.roche.com/global/en/products/params/electsys-anti-sars-cov-2.html>. Accessed
244 February 15 2021.
- 245 8. Roche Molecular Systems Inc. cobas® SARS-CoV-2 Qualitative assay for use on the cobas®
246 6800/8800 Systems. 09179917001-05EN. Doc Rev. 5.0 2020. Available from:
247 <https://www.fda.gov/media/136049/download>. Accessed February 11 2021.
- 248 9. Nörz D, Frontzek A, Eigner U, Oestereich L, Fischer N, Aepfelbacher M, et al. Pushing beyond
249 specifications: Evaluation of linearity and clinical performance of a fully automated SARS-CoV-2 RT-
250 PCR assay for reliable quantification in blood and other materials outside recommendations.
251 *medRxiv.* 2020:2020.05.28.20115469.
- 252 10. Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. *BMJ.*
253 1994;308(6943):1552.
- 254 11. Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H.
255 Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. *Journal*
256 *of Clinical Virology.* 2020;129:104455.
- 257 12. Corman VM, Haage VC, Bleicker T, Schmidt ML, Mühlemann B, Zuchowski M, et al.
258 Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests. *medRxiv.*
259 2020:2020.11.12.20230292.
- 260 13. Krüger LJ, Gaeddert M, Tobian F, Lainati F, Gottschalk C, Klein JAF, et al. Evaluation of the
261 accuracy and ease-of-use of Abbott PanBio - A WHO emergency use listed, rapid, antigen-detecting
262 point-of-care diagnostic test for SARS-CoV-2. *medRxiv.* 2020:2020.11.27.20239699.
- 263 14. Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for COVID-19 infectious
264 potential assessment – a systematic review. *Clinical Infectious Diseases.* 2020;ciaa1764.
- 265 15. Woelfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Mueller MA, et al. Clinical
266 presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-
267 associated transmission cluster. *medRxiv.* 2020:2020.03.05.20030502.
- 268 16. Hoehl S, Schenk B, Rudych O, Göttig S, Foppa I, Kohmer N, et al. At-home self-testing of
269 teachers with a SARS-CoV-2 rapid antigen test to reduce potential transmissions in schools. Results of
270 the SAFE School Hesse Study. 2020:2020.12.04.20243410.

SARS-CoV-2 antigen immunoassay manuscript submitted 9 April

- 271 17. Weitzel T, Legarraga P, Iruretagoyena M, Pizarro G, Vollrath V, Araos R, et al. Head-to-head
272 comparison of four antigen-based rapid detection tests for the diagnosis of SARS-CoV-2 in respiratory
273 samples. *bioRxiv*. 2020:2020.05.27.119255.
- 274 18. Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, et al. Comparison of
275 automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313
276 nasopharyngeal swabs, including from seven serially followed patients. *International Journal of*
277 *Infectious Diseases*. 2020;99:397–402.
- 278

279 **Figures and Tables**

280 **Table 1. Sensitivity and specificity results for the Elecsys SARS-CoV-2 Antigen assay**

281

	cobas SARS-CoV-2 assay	N total	Elecsys SARS-CoV-2 Antigen negative	Elecsys SARS-CoV-2 Antigen positive	Relative sensitivity/specificity, % (95% CI two-sided)
Relative sensitivity	T2 PCR positive	392*	156	236	60.2 (55.2–65.1)
	T2 >10 ⁴ copies/mL (~Ct <29.9)	223	14	209	93.7 (89.7–96.5)
	T2 >10 ⁵ copies/mL (~Ct <26.6)	171	0	171	100 (97.9–100)
	T2 >10 ⁶ copies/mL (~Ct <23.0)	122	0	122	100 (97.0–100)
Relative specificity	PCR negative	2747**	2743	4	99.9 (99.6–100)

282

283 *2 samples with Ct values only for cobas SARS-CoV-2 Target-1, considered for titer <10³ copies/mL;

284 **15 samples invalid with cobas SARS-CoV-2 RT-PCR, but negative with another SARS-CoV-2 RT-PCR test.

285

286 CI, confidence interval; Ct, cycle threshold; N, number of samples; T2, Target-2

287 **Figure 1.**

288 A. Number of positive samples relative to cobas SARS-CoV-2 PCR titer [copies/mL].

289 B. COI values of Elecsys SARS-CoV-2 Antigen test from 2747 cobas SARS-CoV-2 PCR-negative and 392 cobas SARS-CoV-2 PCR-positive samples.

290

SARS-CoV-2 antigen immunoassay manuscript submitted 9 April


291 **Figure 2.**

292 A. Elecsys SARS-CoV-2 Antigen results in relation to cobas SARS-CoV-2 RNA copies/mL. Dark grey
293 fields represent positive and light grey fields negative Elecsys SARS-CoV-2 Antigen. On left side,
294 sensitivity was calculated every ≈ 20 samples included in the interval of the heatmap (copies/mL).

295 B. Correlation between Elecsys SARS-CoV-2 Antigen assay (\log_{10} [COI], y-axis) and cobas SARS-CoV-2
296 PCR assay (\log_{10} [RNA copies/mL], x-axis). Closed circles: measurements within linear range of
297 Target-2, considered for the trendline and correlation (SARS-CoV-2 RNA $\geq 10^5$ copies/mL; COI ≥ 1).
298 Open circles: measurements outside of the linear range of Elecsys SARS-CoV-2 or one cobas SARS-
299 CoV-2 PCR Target negative, not considered for trendline and correlation. $p < 0.0001$; $r^2 = 0.786$.


300 Ag, antigen; COI, cut-off index; Ct, cycle threshold

301



A) Number of positive samples dependent on SARS-CoV-2 PCR Titer [cp/ml]; **B)** COI Elecsys SARS-CoV-2 Antigen from 2747 cobas SARS-CoV-2 PCR negative and 392 cobas SARS-CoV-2 PCR positive samples.

A



B

